PARP1 and cancer: To further improve therapeutic outcomes, it is important to improve our understanding of HR-deficient cancers and find agents that target the acquired vulnerabilities of PARP inhibitor-resistant tumors, delay the onset of resistance, or selectively kill unresponsive cells.